This Lifesciences Company Secures USFDA Approval for Eluxadoline Tablets with 180-Day Exclusivity; Stock Price Logged 135.25 per cent Returns in 3 years
This Lifesciences Company Secures USFDA Approval for Eluxadoline Tablets with 180-Day Exclusivity; Stock Price Logged 135.25 per cent Returns in 3 years

This Lifesciences Company Secures USFDA Approval for Eluxadoline Tablets with 180-Day Exclusivity; Stock Price Logged 135.25 per cent Returns in 3 years

With a PE ratio of 20x, the company trades at a discount compared to the industry PE of 28x. The company has ROCE of 22.3 per cent and ROE of 20.7 per cent.  

DSIJ Intelligence-2 Article rating: 5.0
New Drug Launch: Transforming Cardiometabolic Care in India
New Drug Launch: Transforming Cardiometabolic Care in India

New Drug Launch: Transforming Cardiometabolic Care in India

Glenmark Pharmaceuticals Ltd, a prominent global pharmaceutical company, has expanded its cardiometabolic portfolio by launching Empagliflozin and its fixed-drug combinations in India.

DSIJ Intelligence-1 Article rating: 5.0

The company continues to strengthen its presence in the cardiometabolic care segment, addressing the rising prevalence of diabetes and cardiovascular diseases in India.

This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.
This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

DSIJ Intelligence Article rating: 3.7

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

Don’t miss the action in this pharmaceutical stock: The Cup and handle pattern breakout is seen with huge volumes!
Don’t miss the action in this pharmaceutical stock: The Cup and handle pattern breakout is seen with huge volumes!

Don’t miss the action in this pharmaceutical stock: The Cup and handle pattern breakout is seen with huge volumes!

Notably, the RSI has entered a super bullish territory, indicating a significant shift in momentum.

DSIJ Intelligence-3 Article rating: 4.7

The Nifty Pharmaceutical index has surged by an impressive 30 per cent on a year-to-date basis in 2023, significantly outperforming the Nifty 50 index. Against the backdrop of India experiencing a single-day spike of 628 new COVID-19 cases

Stocks to watch: These small-cap stocks will be in focus on Friday!
Stocks to watch: These small-cap stocks will be in focus on Friday!

Stocks to watch: These small-cap stocks will be in focus on Friday!

Among the BSE Smallcap gainers were Astec Lifesciences, Syncom Formulations, Suzlon Energy and NBCC

DSIJ Intelligence Article rating: 4.1

On Wednesday, the Sensex gained by 346 points to close at 57,960.09, while the Nifty 50 surged by 129 points to close at 17,080.70

Overnight Digest: Stocks to be watched on August 12
Overnight Digest: Stocks to be watched on August 12

Overnight Digest: Stocks to be watched on August 12

Keep an eye on these stocks for Friday's trading session.

DSIJ Intelligence Article rating: 4.3

Benchmark indices registered a positive close on Thursday with Sensex gaining 500 points while Nifty advancing 124 points. 

RSS
12

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR